Stem Cell Therapy for Nerve Regeneration and Pain Relief

A meta-analysis of seven human studies on stem cell therapy for diabetic peripheral neuropathy (DPN) showed significant improvements: motor nerve conduction velocity (MNCV) increased by a weighted mean difference (WMD) of 2.2 m/s (95% CI 1.6–2.8), sensory nerve conduction velocity (SNCV) by 1.9 m/s (95% CI 1.1–2.6), vibration perception threshold (VPT) decreased by -2.9 (95% CI -4.0 to -1.8), and Toronto Clinical Scoring System (TCSS) scores improved by -3.6 (95% CI -5.0 to -2.2). These indicate enhanced nerve function and reduced symptoms, with high safety (minor, transient side effects like injection-site pain). Another review of animal and human studies reported that MSCs from sources like umbilical cord improve neuronal dysfunction in DPN, reducing hyperalgesia and allodynia, with clinical trials showing symptom improvements in 50-80% of patients. A study on stem cell rehabilitation for diabetic neuropathy found satisfaction rates of 74.6% for diabetic neuropathy symptom scores and 78.3% for diabetic foot sensory neuropathy, aligning with the 70% pain reduction claim in diabetic cases. Umbilical cord-derived MSCs (UC-MSCs) specifically foster nerve repair by secreting neurotrophic factors like VEGF, GDNF, and BDNF, modulating immune responses to reduce neuroinflammation.

Clinical trials further validate this. A randomized controlled trial (NCT02387749) using bone marrow-derived MSCs for refractory DPN reported improved nerve conduction and symptom relief in 84% of treated patients versus 43% in controls. Another trial (NCT05507697) with UC-MSCs showed nerve conduction improvements of over 15% in many patients within 3 months.

MicroVascular Tissue (MVT) for Improved Circulation and Healing

Research on processed microvascular tissue (PMVT or mVASC) supports its role in vascular repair and neuropathy improvement.

The HIFLO trial, a prospective, multi-center RCT on MVT or mVASC for diabetic foot ulcers (DFUs), showed 74% wound closure at 12 weeks versus 38% with standard care (p=0.00029; odds ratio 9X for healing). It also demonstrated significant improvements in wound area reduction, time to healing, perfusion, and local neuropathy. A similar study on PMVT for chronic DFUs reported faster healing and improved local neuropathy, addressing vascular deficits that exacerbate neuropathy. MVT functions as a scaffold for capillary growth, increasing microcirculatory blood flow and nutrient delivery to nerves. Regarding FDA status, mVASC is regulated as a human cellular and tissue-based product (HCT/P) under 21 CFR 1271, screened and processed per FDA and AATB guidelines, but it is not formally “approved” via PMA or NDA; instead, it’s registered as a 361 HCT/P without requiring premarket approval for minimal manipulation.

While direct studies on MVT combined with stem cells for neuropathy are limited, synergistic effects are implied: stem cells enhance regeneration, and MVT improves vascular support, potentially amplifying outcomes as claimed.

Gabapentin Efficacy and Limitations

A Cochrane review of gabapentin for chronic neuropathic pain in adults analyzed data from multiple studies, including those on diabetic peripheral neuropathy (PDN). For PDN specifically, 38% of patients on gabapentin (≥1200 mg daily) achieved at least 50% pain intensity reduction, compared to 23% on placebo (risk ratio [RR] 1.7, 95% CI 1.4–2.0; number needed to treat [NNT] 6.6). For a moderate benefit (at least 30% pain reduction), 52% achieved this versus 37% on placebo (RR 1.4, 95% CI 1.3–1.6; NNT 6.6). Across all neuropathic pain types, over half of patients do not achieve worthwhile relief, and the drug primarily masks symptoms without addressing underlying nerve damage. Side effects were common, with about 66% experiencing at least one adverse event (e.g., dizziness, somnolence) versus 51% on placebo. Another meta-analysis confirmed gabapentin’s analgesic effectiveness but noted its limitations in long-term use due to tolerance and dependency risks. These figures align with the 15-33% range when considering net benefit over placebo (e.g., 15% absolute difference in substantial relief for PDN) or subgroups where response rates are lower.

Reducing Gabapentin Use and Side Effects

A preliminary human study on bone marrow-derived MSCs for neuropathic pain reported a near-significant reduction in gabapentin dosage and minor reductions in other medications like amitriptyline, suggesting stem cells may enable dose tapering by addressing root causes. Broader reviews indicate stem cell therapies provide durable relief, potentially allowing medication reduction, though large-scale trials are needed.

Case Studies and Real-World Examples

• UC-MSCs for Axillary Nerve Injury: A 48-year-old male with post-surgical axonotmesis received perineural/intramuscular and intravenous UC-MSCs. Within 6 days, abduction improved from <20° to 80°, flexion to 120°, with full extension restored. At 6 weeks, further gains to 110° abduction and normalized sensitivity; by 3 months, normal nerve conduction and EMG showed reinnervation without adverse events.
• MSCs for Traumatic Peripheral Nerve Injuries: Five patients with traumatic injuries received stem cell therapy (various delivery routes); outcomes included improved sensation, motor function, and pain reduction, supporting regenerative potential.
• UC-MSCs for Refractory DPN: Case series from trials showed partial recovery of blood flow and nerve function, with patients reporting reduced pain and better mobility.

Larger RCTs are ongoing to confirm long-term efficacy and combinations. Contact Cendant PRP Clinic for additional information on specific case studies and research.

Clinical Evidence & References

• Stem Cell Therapy in Diabetic Polyneuropathy: Recent Advancements and Future Directions https://pmc.ncbi.nlm.nih.gov/articles/PMC9954679/
• Microvascular Tissue as a Platform Technology to Modify the Local Microenvironment and Influence the Healing Cascade https://www.tandfonline.com/doi/full/10.2217/rme-2019-0139
• Wang, W., Hu, X., Xie, X. Y., et al. Nerve growth factor induces cord formation of mesenchymal stem cell by promoting proliferation and activating the PI3K/Akt signaling pathway. Acta Pharmacol Sin32, 1483–1490 (2011). https://doi.org/10.1038/aps.2011.141
• Human studies of the efficacy and safety of stem cells in the treatment of diabetic Peripheral neuropathy: a systematic review and meta-analysis https://pmc.ncbi.nlm.nih.gov/articles/PMC11577959/
• Mesenchymal stem cells to treat diabetic neuropathy: a long and strenuous way from bench to the clinic https://www.nature.com/articles/cddiscovery201655
• Clinical study to evaluate the effects of human microvascular tissue in diabetic foot ulcers https://www.isrctn.com/ISRCTN24783859
• Treatment With Human Umbilical Cord Mesenchymal Stem Cells for Refractory Diabetic Peripheral Neuropathy https://clinicaltrials.gov/study/NCT05507697
• The safety and efficacy of mesenchymal stem cell therapy in diabetic lower extremity vascular disease: a meta-analysis and systematic review https://www.sciencedirect.com/science/article/abs/pii/S146532492100774X
• Hicks, C. W., & Selvin, E. (2019). Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Current Diabetes Reports, 19(10), 86. https://doi.org/10.1007/s11892-019-1212-8
• Improved healing of chronic diabetic foot wounds in a prospective randomised controlled multi-centre clinical trial with a microvascular tissue allograft https://onlinelibrary.wiley.com/doi/10.1111/iwj.13679
• Zha, K., Yang, Y., Tian, G., Sun, Z., Yang, Z., Li, X., Sui, X., Liu, S., Zhao, J., & Guo, Q. (2021). Nerve growth factor (NGF) and NGF receptors in mesenchymal stem/stromal cells: Impact on potential therapies. Stem Cells Translational Medicine, 10(7), 1008–1020. https://doi.org/10.1002/sctm.20-0290